People with obesity are under-represented in randomized clinical trials (RCTs) of drugs used to treat acute bacterial skin and skin structure infections (ABSSSIs) in the United States, according to findings published in Open...
The global treatment market for acute bacterial skin and skin structure infections (ABSSSI) is projected to increase at a compound annual growth rate of 9.6%, for an incremental revenue of $23.3 billion by 2032, according to a...